Inverness Counsel LLC NY increased its stake in Pfizer Inc. (NYSE:PFE) by 15.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 21,544 shares of the biopharmaceutical company’s stock after buying an additional 2,919 shares during the period. Inverness Counsel LLC NY’s holdings in Pfizer were worth $759,000 at the end of the most recent reporting period.
Several other large investors also recently added to or reduced their stakes in PFE. Bloom Tree Partners LLC acquired a new position in Pfizer during the first quarter valued at about $35,682,000. BlackRock Group LTD boosted its position in Pfizer by 5.6% in the first quarter. BlackRock Group LTD now owns 59,474,971 shares of the biopharmaceutical company’s stock valued at $1,762,838,000 after buying an additional 3,154,116 shares during the last quarter. Franklin Resources Inc. boosted its position in Pfizer by 16.7% in the first quarter. Franklin Resources Inc. now owns 62,902,993 shares of the biopharmaceutical company’s stock valued at $1,864,446,000 after buying an additional 9,005,107 shares during the last quarter. NN Investment Partners Holdings N.V. acquired a new position in Pfizer during the first quarter valued at about $242,144,000. Finally, BlackRock Fund Advisors boosted its position in Pfizer by 1.5% in the first quarter. BlackRock Fund Advisors now owns 92,489,121 shares of the biopharmaceutical company’s stock valued at $2,741,378,000 after buying an additional 1,403,646 shares during the last quarter. Institutional investors and hedge funds own 69.65% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) traded down 0.27% during midday trading on Friday, reaching $33.56. The company’s stock had a trading volume of 14,819,706 shares. Pfizer Inc. has a 12 month low of $28.25 and a 12 month high of $37.39. The stock has a market capitalization of $203.56 billion, a P/E ratio of 29.75 and a beta of 0.86. The stock’s 50-day moving average is $34.29 and its 200 day moving average is $34.19.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The business had revenue of $13.10 billion for the quarter, compared to the consensus estimate of $13.01 billion. During the same quarter in the previous year, the company posted $0.56 earnings per share. Pfizer’s revenue for the quarter was up 10.9% compared to the same quarter last year. On average, analysts expect that Pfizer Inc. will post $2.46 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be paid a $0.30 dividend. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a yield of 3.58%. Pfizer’s dividend payout ratio (DPR) is currently 95.24%.
Several analysts have weighed in on the company. Argus reissued a “buy” rating and issued a $39.00 target price on shares of Pfizer in a report on Tuesday. Bank of America Corp. reissued a “buy” rating and issued a $40.00 target price on shares of Pfizer in a report on Tuesday, September 27th. Sanford C. Bernstein reissued an “outperform” rating on shares of Pfizer in a report on Monday, September 26th. Jefferies Group lowered their target price on Pfizer from $40.00 to $39.00 and set a “buy” rating on the stock in a report on Tuesday, September 13th. Finally, Piper Jaffray Cos. set a $54.00 target price on Pfizer and gave the company a “buy” rating in a report on Tuesday, August 23rd. Ten equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $38.78.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.